Rates of antimicrobial resistance in latin america (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics

Abstract

. Argentina and Mexico were the greatest contributors of isolates to this study. Susceptibilities were determined according to Clinical Laboratory Standards Institute guidelines. Resistance levels were high for most key organisms across Latin America: 48.3% of Staphylococcus aureus isolates were methicillin-resistant while 21.4% of Acinetobacter spp. isolates were imipenem-resistant. Extended-spectrum β β β β β-lactamase were reported in 36.7% of Klebsiella pneumoniae and 20.8% of E. coli isolates. Tigecycline was the most active agent against Gram-positive isolates. Tigecycline was also highly active against all Gram-negative organisms, with the exception of Pseuodomonas aeruginosa, against which piperacillin-tazobactam was the most active agent tested (79.3% of isolates susceptible). The in vitro activity of tigecycline against both Gram-positive and Gram-negative isolates indicates that it may be an useful tool for the treatment of nosocomial infections, even those caused by organisms that are resistant to other antibacterial agents.

Emergence and clonal dissemination of carbapenem-hydrolysing OXA-58-producing Acinetobacter baumannii isolates in Bolivia

“…It was difficult to compare the results in this study with those in other regions due to the lack of published reports. However, the observed percentage of carbapenem-resistant isolates was similar to that found in 2004 in Argentina (39.3 %), Venezuela (36.4 %), Brazil (31.1 %) and Colombia (30.8 %) (Rossi et al, 2008;Sader et al, 2004;Sgambatti et al, 2010;Tognim et al, 2004). In contrast, our results were different from those found for carbapenem resistance in isolates in Chile (6.5 %), Mexico (1.1 %) or Guatemala, Honduras, Panama, Puerto Rico and Jamaica where no carbapenem-resistant isolates were found (Tognim et al, 2004).…”

Prevalence of resistance phenotypes in Staphylococcus aureus and coagulase-negative isolates of venous ulcers of primary healthcare patients

“…The multi-drug resistance of the hospital MRSA isolates has also been verified in other studies, however in strains obtained from hospitals [25][26][27] . All the MRSA isolated in this study were resistant to cefoxitin on the antibiogram (marker) and confirmed by the E-test®.…”

“…isolated from venous ulcers of patients treated in outpatient clinics in Brazil as well as in other countries. On the other hand, the prevalence of the identified pathogens ranges significantly in the health centers of different countries and in the same region [26][27][28][29][30][31] . Different services have different conditions, and, for this reason, comparisons are not pertinent.…”

Revisión sistemática de la resistencia antimicrobiana en enterobacterias en aislamientos intrahospitalarios en Colombia

“…Con base en los estudios identificados, en los últimos años (2009 a 2011) la frecuencia de BLEE podría situarse entre 10,1 y 11,8 % en E. coli y entre 14,6 y 32,6 % en K. pneumoniae. A nivel mundial, los datos del estudio TEST (Tigecycline Evaluation and Surveillance Trial) (56)(57)(58)(59), los del proyecto Sentry (60) y los del estudio SMART (Study for Monitoring Antimicrobial Resistance Trends) muestran cómo en la última década las tasas más altas se observan en Asia, seguidas por las de América Latina y, por último, las de los países desarrollados (61)(62)(63). Al comparar la situación de Colombia con los datos reportados, en el caso de K. pneumoniae productora de BLEE el país estaría al nivel de América Latina, con las tasas de resistencia más altas.…”